下调和上调
前列腺癌
前列腺切除术
生化复发
癌症研究
小RNA
细胞生长
前列腺
免疫印迹
生物
LNCaP公司
癌症
医学
内科学
基因
生物化学
遗传学
作者
Bin Zhan,Linjin Huang,Yachun Chen,Wen Ye,Jingkun Li,Jianhui Chen,Sheng Yang,Wei Jiang
出处
期刊:The Prostate
[Wiley]
日期:2020-07-06
卷期号:80 (12): 1024-1037
被引量:14
摘要
Abstract Background Dysregulation of microRNAs has performed vital gene regulatory functions in the genesis, progression, and prognosis of multiple malignant tumors. This study aimed to elucidate the regulatory mechanism of miR‐196a in prostate cancer (PCa) and explore its clinical significance. Methods Quantitative real‐time polymerase chain reaction was implemented to examine miR‐196a and p27 kip1 messenger RNA expression in PCa. Cell proliferation was evaluated via Cell Counting Kit‐8, colony formation, and nude mouse tumorigenicity assays. Luciferase reporter assay was applied to identify target genes. p27 kip1 protein expression in PCa was investigated using Western blot analysis and immunohistochemistry. Results There was a dramatic upregulation of miR‐196a in PCa. Upregulated miR‐196a was related to worse Gleason score (GS), later pathological stage, and poor biochemical recurrence (BCR)‐free survival. In vivo and in vitro experiments exhibited that miR‐196a promoted PCa proliferation and expedited G1/S‐phase progression through the downregulation of p27 kip1 protein. Additionally, p27 kip1 protein was distinctly downregulated in PCa. Low p27 kip1 protein expression had a strong correlation with increased GS and was an independent predictor of BCR after radical prostatectomy (RP). Conclusions Excessive expression of miR‐196a and subsequent downregulation of p27 kip1 protein play essential roles in promoting PCa proliferation and leading to BCR after RP. miR‐196a and its target p27 kip1 may become novel molecular biomarkers and therapeutic targets for PCa.
科研通智能强力驱动
Strongly Powered by AbleSci AI